Smithtown Assisted Living
(516) 265-7793
PD-L1 Inhibitor Tops Docetaxel for Survival in NSCLC (CME/CE)
(MedPage Today) -- Consistent benefit with atezolizumab, irrespective of ligand expression
via
PD-L1 Inhibitor Tops Docetaxel for Survival in NSCLC (CME/CE)
by
Newer Post
Older Post
Home